Stock comparison
JOHNSON & JOHNSON is 297.9x more valuable than AbCellera Biologics Inc. by market capitalization ($618.61 B vs $2.08 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
JNJ is larger
JOHNSON & JOHNSON is 297.9x more valuable than AbCellera Biologics Inc. by market capitalization ($618.61 B vs $2.08 B).
Market value leader
JNJ
JOHNSON & JOHNSON is 297.9x more valuable than AbCellera Biologics Inc. by market capitalization ($618.61 B vs $2.08 B).
Revenue leader
JNJ
ABCL: $75.13M vs JNJ: $94.19B.
Profit leader
JNJ
ABCL: -$146.41M vs JNJ: $26.80B.
Margin leader
JNJ
ABCL: -194.9% vs JNJ: 28.5% net margin.
| Metric | ABCL | JNJ |
|---|---|---|
| Market cap | $2.08 B | $618.61 B |
| US-listed rank | #2103 | #18 |
| Revenue (latest FY) | $75.13M | $94.19B |
| Net income (latest FY) | -$146.41M | $26.80B |
| Net margin | -194.9% | 28.5% |
| P/E (trailing FY) | - | 23.1x |
| SEC filings | 297 | 990 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
JOHNSON & JOHNSON is 297.9x more valuable than AbCellera Biologics Inc. by market capitalization ($618.61 B vs $2.08 B).
In their latest fiscal years, AbCellera Biologics Inc. reported $75.13M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: AbCellera Biologics Inc. and JOHNSON & JOHNSON, or browse the full rankings.